Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSCA-CAR-T cells for castration-resistant prostate cancer
ChiCTR1800018277Phase 2Recruiting
- Sponsor
- Hebei General Hospital
- Start
- Oct 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous PSCA-CAR-T cells in castration-resistant prostate cancer (CRPC) (4 arms), sponsored by Hebei General Hospital. Primary endpoints: Adverse events and Tumor load. Started Oct 2018; status: recruiting.
02
Drugs
autologous PSCA-CAR-T cells
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ChiCTR1800018277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018277.